The Study of Abatacept in Combination With Etanercept

Phase 2

Completed

• Conditions: Rheumatoid Arthritis

• Registration Number: NCT00162279
• Lead Sponsor: Bristol-Myers Squibb

Brief Summary

The Study was designed to look at the safety and efficacy of abatacept in combination with etanercept.

Detailed Description

Not available

Study Timeline

• Study Start: 2000-10
• Study First Submitted: 2005-09-09
• Study First Submitted QC: 2005-09-09
• Study First Posted: 2005-09-13
• Primary Completion: 2007-02
• Study Completion: 2007-02
• Disposition First Submitted: 2010-09-10
• Disposition First Submitted QC: 2010-09-10
• Disposition First Posted: 2010-09-14
• Status Verified: 2010-12
• Last Update Submitted: 2010-12-02
• Last Update Posted: 2010-12-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 141

Inclusion Criteria

• All subjects who had completed the short term portion of IM101-101.

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Abatacept combined with etanercept will have greater clinical efficacy compared to subjects receiving etanercept alone	at 6 months

Secondary Outcome Measures

Name	Time	Method
ACR 50 and 70 will be evaluated	at 6 months

Trial Locations

Locations (1)

Local Institution; 🇺🇸 Glendale, Wisconsin, United States